- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What You May Have Missed at RAD 2023
The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.
These are the top news items from the 2023 Revolutionizing Atopic Dermatitis (RAD) meeting, which took place in Washington, DC, from April 29 to May 1.
Panel Focuses on Burgeoning Therapies in Atopic Dermatitis
A panel held at RAD 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Symposium Highlights New Research on JAK, PDE-4 Inhibitors
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the RAD fifth annual conference.
Dr Melinda Gooderham Discusses Emerging Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Dr Robert Sidbury: How to Treat Facial Atopic Dermatitis in Infants
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discussed treatment approaches for AD of the face in infancy.
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
